Creating A RIsk Assessment Biomarker Tool to Prevent Seasonal and Thunderstorm Asthma: The CARISTA Study

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Thunderstorm asthma is a recurring public health emergency in South-Eastern Australia which occurs in springtime. The major identified risk factors for thunderstorm asthma is hay fever and allergy to ryegrass pollen. The goal of the CARISTA study is to identify the risk of springtime allergic and thunderstorm asthma in allergic adults living in South-Eastern Australia. To do this the investigators will recruit 530 people who have hay fever and test them for allergy to ryegrass pollen and undertake simple lung function testing. The investigators will ask study participants to complete a customised symptom tracker over the springtime pollen season for 2 consecutive years. The outcome the investigators are looking for is an asthma exacerbation or worsening asthma symptoms. This study will enable the investigators to identify indicators (biomarkers) of severe and moderate asthma exacerbations in order to identify those at risk of thunderstorm and seasonal asthma so protective treatments and strategies can be advised.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: t
View:

⁃ Consenting adults aged 18 to 70 years with seasonal allergic rhinitis

⁃ willing to undertake:

• Lung function testing

• Blood sample collection for risk factor identification, -Prospectively logging their symptoms and medications through the springtime season using the CARISTA symptom monitoring platform . -

Locations
Other Locations
Australia
The Royal Melbourne Hospital
RECRUITING
Parkville
Contact Information
Primary
Jo A Douglass, MD
jdouglass@unimelb.edu.au
+6183444578
Backup
Rachel Tham, PhD
CARISTA-Study@unimelb.edu.au
+61390356053
Time Frame
Start Date: 2025-08-27
Estimated Completion Date: 2030-12-31
Participants
Target number of participants: 530
Treatments
Other: Observational
prospective observational cohort
Related Therapeutic Areas
Sponsors
Collaborators: Monash Medical Centre, Western Hospital, Australia, Northern Hospital, Australia, Melbourne Health, Austin Hospital, Melbourne Australia, The Alfred, Eastern Health, Queensland University of Technology
Leads: University of Melbourne

This content was sourced from clinicaltrials.gov